Biggest Investing Moment...
Man Who Called Tesla & Bitcoin: "Nobody is Paying Attention to This"
Click here to see what you are missing

Samuel Bates Martin Insider Information

Mr. Martin joined Celldex in April 2009 as Director of Financial Reporting, Planning and Analysis and most recently served as Vice President, Finance. Prior to joining Celldex, Mr. Martin served as the Director of Finance and Corporate Compliance for Alseres Pharmaceuticals, where he was responsible for managing the financial and SEC reporting and the annual budget and planning process. Mr. Martin began his career at Ernst & Young, holding various positions prior to completing his tenure as Audit Manager, where he provided audit, review, due diligence and consulting services to public and private companies in the biotechnology, medical device, health care, high technology, manufacturing and consumer product industries. Mr. Martin received an M.B.A. from Boston University, a B.S. from Skidmore College and is a Certified Public Accountant.

How do I contact Samuel Bates Martin?

The corporate mailing address for Mr. Martin and other Celldex Therapeutics executives is 53 FRONTAGE ROAD SUITE 220, HAMPTON NJ, 08827. Celldex Therapeutics can also be reached via phone at (908) 200-7500 and via email at [email protected]

Has Samuel Bates Martin been buying or selling shares of Celldex Therapeutics?

During the past quarter, Samuel Bates Martin has sold $123,894.00 in shares of Celldex Therapeutics stock. Most recently, Samuel Bates Martin sold 2,738 shares of the business's stock in a transaction on Tuesday, August 10th. The shares were sold at an average price of $45.25, for a transaction totalling $123,894.50.

Who are Celldex Therapeutics' active insiders?

Celldex Therapeutics' insider roster includes Freddy Jimenez (SVP), and Samuel Martin (CFO).

Are insiders buying or selling shares of Celldex Therapeutics?

In the last year, Celldex Therapeutics insiders bought shares 1 times. They purchased a total of 430 shares worth mmore than $19,900.40. In the last year, insiders at the biopharmaceutical company sold shares 2 times. They sold a total of 23,570 shares worth mmore than $511,578.02. The most recent insider tranaction occured on August, 11th when Freddy A Jimenez SVP bought 430 shares worth more than $19,900.40. Insiders at Celldex Therapeutics own 1.9 % of the company.

Information on this page was last updated on 8/11/2021.

Samuel Bates Martin Insider Trading History at Celldex Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/10/2021Sell2,738$45.25$123,894.50View SEC Filing Icon  
6/9/2020Buy9,750$2.99$29,152.50View SEC Filing Icon  
See Full Table

Samuel Bates Martin Buying and Selling Activity at Celldex Therapeutics

This chart shows Samuel Bates Martin's buying and selling at Celldex Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Celldex Therapeutics Company Overview

Celldex Therapeutics logo
Celldex Therapeutics, Inc. engages in the business of development, manufacturing and commercialization of novel therapeutics for human health care. Its drug candidates have the ability to engage the human immune system and directly inhibit tumors to treat specific types of cancer and other diseases. Its pipeline includes Varlilumab, CDX-1140, and CDX-301, and CDX-3379. The company was founded by Anthony S. Marucci and Tibor Keler in 1983 and is headquartered in Hampton, NJ.
Read More

Today's Range

Now: $55.21
Low: $54.65
High: $56.14

50 Day Range

MA: $48.75
Low: $39.85
High: $55.99

2 Week Range

Now: $55.21
Low: $11.88
High: $56.17

Volume

267,934 shs

Average Volume

706,180 shs

Market Capitalization

$2.57 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

3.06
Early Investors: Holographic "Phones" Are Coming...
Is that coffee machine real or digital?

To potentially profit, click before Oct. 27th.
Learn more.
pixel